178 related articles for article (PubMed ID: 37871574)
21. Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model.
Makuuchi Y; Nakashima Y; Nishimoto M; Koh H; Hino M; Nakamae H
Exp Hematol; 2023 Jul; 123():56-65. PubMed ID: 37098360
[TBL] [Abstract][Full Text] [Related]
22. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.
Ghosh A; Smith M; James SE; Davila ML; Velardi E; Argyropoulos KV; Gunset G; Perna F; Kreines FM; Levy ER; Lieberman S; Jay HV; Tuckett AZ; Zakrzewski JL; Tan L; Young LF; Takvorian K; Dudakov JA; Jenq RR; Hanash AM; Motta AC; Murphy GF; Liu C; Schietinger A; Sadelain M; van den Brink MR
Nat Med; 2017 Feb; 23(2):242-249. PubMed ID: 28067900
[TBL] [Abstract][Full Text] [Related]
23. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.
Saha A; O'Connor RS; Thangavelu G; Lovitch SB; Dandamudi DB; Wilson CB; Vincent BG; Tkachev V; Pawlicki JM; Furlan SN; Kean LS; Aoyama K; Taylor PA; Panoskaltsis-Mortari A; Foncea R; Ranganathan P; Devine SM; Burrill JS; Guo L; Sacristan C; Snyder NW; Blair IA; Milone MC; Dustin ML; Riley JL; Bernlohr DA; Murphy WJ; Fife BT; Munn DH; Miller JS; Serody JS; Freeman GJ; Sharpe AH; Turka LA; Blazar BR
J Clin Invest; 2016 Jul; 126(7):2642-60. PubMed ID: 27294527
[TBL] [Abstract][Full Text] [Related]
24. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.
Asakura S; Hashimoto D; Takashima S; Sugiyama H; Maeda Y; Akashi K; Tanimoto M; Teshima T
J Clin Invest; 2010 Jul; 120(7):2370-8. PubMed ID: 20530875
[TBL] [Abstract][Full Text] [Related]
25. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers.
Schilbach K; Schick J; Wehrmann M; Wollny G; Simon P; Schlegel PG; Eyrich M
Transplantation; 2007 Jul; 84(2):214-22. PubMed ID: 17667813
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
[TBL] [Abstract][Full Text] [Related]
27. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
[TBL] [Abstract][Full Text] [Related]
28. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.
Betts BC; Bastian D; Iamsawat S; Nguyen H; Heinrichs JL; Wu Y; Daenthanasanmak A; Veerapathran A; O'Mahony A; Walton K; Reff J; Horna P; Sagatys EM; Lee MC; Singer J; Chang YJ; Liu C; Pidala J; Anasetti C; Yu XZ
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1582-1587. PubMed ID: 29382747
[TBL] [Abstract][Full Text] [Related]
29. Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80.
Cassady K; Martin PJ; Zeng D
Front Immunol; 2018; 9():3061. PubMed ID: 30622541
[TBL] [Abstract][Full Text] [Related]
30. Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease.
Zhang Y; Sandy AR; Wang J; Radojcic V; Shan GT; Tran IT; Friedman A; Kato K; He S; Cui S; Hexner E; Frank DM; Emerson SG; Pear WS; Maillard I
Blood; 2011 Jan; 117(1):299-308. PubMed ID: 20870902
[TBL] [Abstract][Full Text] [Related]
31. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.
Juchem KW; Sacirbegovic F; Zhang C; Sharpe AH; Russell K; McNiff JM; Demetris AJ; Shlomchik MJ; Shlomchik WD
J Immunol; 2018 Jan; 200(2):834-846. PubMed ID: 29212909
[TBL] [Abstract][Full Text] [Related]
33. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
34. Expression of Id3 represses exhaustion of anti-tumor CD8 T cells in liver cancer.
Jin Y; Hu P; Sun H; Yang C; Zhai J; Wang Y; Chu X; Sun Z; Wang J; Sun J; Wang J
Mol Immunol; 2022 Apr; 144():117-126. PubMed ID: 35219016
[TBL] [Abstract][Full Text] [Related]
35. PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade.
Ikegawa S; Meguri Y; Kondo T; Sugiura H; Sando Y; Nakamura M; Iwamoto M; Maeda Y; Matsuoka KI
Blood Adv; 2019 Dec; 3(23):4081-4094. PubMed ID: 31821459
[TBL] [Abstract][Full Text] [Related]
36. Loss of B7-H1 expression by recipient parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence of graft-versus-host disease.
Li X; Deng R; He W; Liu C; Wang M; Young J; Meng Z; Du C; Huang W; Chen L; Chen Y; Martin P; Forman S; Zeng D
J Immunol; 2012 Jan; 188(2):724-34. PubMed ID: 22156590
[TBL] [Abstract][Full Text] [Related]
37. A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.
He S; Cao Q; Qiu Y; Mi J; Zhang JZ; Jin M; Ge H; Emerson SG; Zhang Y; Zhang Y
J Immunol; 2008 Dec; 181(11):7581-92. PubMed ID: 19017947
[TBL] [Abstract][Full Text] [Related]
38. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease.
Deng R; Cassady K; Li X; Yao S; Zhang M; Racine J; Lin J; Chen L; Zeng D
J Immunol; 2015 Jan; 194(2):560-74. PubMed ID: 25488990
[TBL] [Abstract][Full Text] [Related]
39. Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice.
Huang Q; He S; Tian Y; Gu Y; Chen P; Li C; Huang J; Liu Y; Yu H; Jin M; Hu S; Tong Q; Ma A; Jin J; Hexner E; Fung H; Reshef R; Zhang Y; Zhang Y
Blood; 2017 May; 129(20):2737-2748. PubMed ID: 28246193
[TBL] [Abstract][Full Text] [Related]
40. Insights into mechanisms of graft-versus-host disease through humanised mouse models.
Elhage A; Sligar C; Cuthbertson P; Watson D; Sluyter R
Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 35993192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
